Bellicum Pharmaceuticals Inc (BLCM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BLCM Annual Balance Sheets →
Balance sheet data covering Bellicum Pharmaceuticals Inc–Sep 30 2022 offers a view into how Sep 30 2023's financial position has changed alongside business activity.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent5.91
Cash & Short-term Investments5.00
Accounts receivable0.02
Prepaid Expense And Other Assets Current0.92
Total Current Assets6.85
Equipment/Property/Plant Net0.01
Other Assets, Noncurrent0.00
Total Assets6.85
Liabilities
Accounts Payable, Current AC0.53
Accrued Liabilities, Current AC1.21
Derivative Liability, Current DE0.52
Total Current Liabilities2.25
Total Long-term Debt0.00
Other liabilities, Noncurrent2.25
Total Liabilities2.25
Stockholders' Equity
Treasury Stock Common Value-5.06
Common Stock Value0.10
Additional Paid In Capital Common Stock569.90
Retained Earnings / Accumulated Deficit-591.61
Other Equity-31.97
Common Stockholder's Equity-58.63
Non-controlling interests & other31.62
Total Stockholder's Equity-27.01
Liabilities & Stockholder's Equity6.85
4 historic quarters locked

Sign in to unlock the full Bellicum Pharmaceuticals Inc balance sheet history.

About Bellicum Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001628280-23-038953

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.